$108.49
0.39% today
NYSE, Feb 28, 05:17 pm CET
ISIN
US66987V1098
Symbol
NVS
Sector
Industry

Novartis ADR Stock price

$108.92
+5.51 5.33% 1M
-10.92 9.11% 6M
+11.61 11.93% YTD
+5.77 5.59% 1Y
+26.12 31.55% 3Y
+27.49 33.75% 5Y
+11.98 12.36% 10Y
NYSE, Closing price Thu, Feb 27 2025
+0.90 0.83%
ISIN
US66987V1098
Symbol
NVS
Sector
Industry

Key metrics

Market capitalization $215.13b
Enterprise Value $233.01b
P/E (TTM) P/E ratio 18.41
EV/FCF (TTM) EV/FCF 14.34
EV/Sales (TTM) EV/Sales 4.63
P/S ratio (TTM) P/S ratio 4.28
P/B ratio (TTM) P/B ratio 4.88
Dividend yield 3.55%
Last dividend (FY25) $3.87
Revenue growth (TTM) Revenue growth 1.08%
Revenue (TTM) Revenue $50.32b
EBIT (operating result TTM) EBIT $15.41b
Free Cash Flow (TTM) Free Cash Flow $16.25b
Cash position $13.46b
EPS (TTM) EPS $5.91
P/E forward 16.68
P/S forward 4.08
EV/Sales forward 4.42
Short interest 0.21%
Show more

Is Novartis ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Novartis ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Novartis ADR forecast:

6x Buy
21%
18x Hold
64%
4x Sell
14%

Analyst Opinions

28 Analysts have issued a Novartis ADR forecast:

Buy
21%
Hold
64%
Sell
14%

Financial data from Novartis ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
50,317 50,317
1% 1%
100%
- Direct Costs 13,045 13,045
10% 10%
26%
37,272 37,272
6% 6%
74%
- Selling and Administrative Expenses 6,497 6,497
26% 26%
13%
- Research and Development Expense 9,301 9,301
8% 8%
18%
21,474 21,474
0% 0%
43%
- Depreciation and Amortization 6,069 6,069
29% 29%
12%
EBIT (Operating Income) EBIT 15,405 15,405
19% 19%
31%
Net Profit 11,941 11,941
20% 20%
24%

In millions USD.

Don't miss a Thing! We will send you all news about Novartis ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novartis ADR Stock News

Neutral
GlobeNewsWire
about 3 hours ago
Basel, February 28, 2025 – Novartis announced today it will present data from 17 abstracts, including investigator-initiated trials, across its immunology portfolio at the 2025 American Academy of Allergy Asthma and Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress and the 2025 American Academy of Dermatology (AAD) Annual Meeting.
Neutral
PRNewsWire
about 3 hours ago
Two-year efficacy and safety data analyses from Phase III SUNSHINE and SUNRISE trials of continuous Cosentyx® (secukinumab) treatment in HS to be presented New analyses of 52-week data from Phase III REMIX pivotal trials of investigational remibrutinib, demonstrating impact in key clinical outcomes for patients with CSU also to be presented Regulatory submissions for remibrutinib as a treatment...
Neutral
GlobeNewsWire
about 4 hours ago
Basel, February 28, 2025 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting a marketing authorization for Fabhalta ®  (iptacopan) – a first-in-class oral Factor B inhibitor of the alternative complement pathway – for the treatment of adults with C3 glomerulopathy...
More Novartis ADR News

Company Profile

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Head office Switzerland
CEO Vasant Narasimhan
Employees 75,883
Founded 1996
Website www.novartis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today